Product Datasheet

CD79A Antibody (IGA/1406) [DyLight 680] NBP2-54370FR

Unit Size: 100 ul

Store at 4C in the dark.

www.novusbio.com



technical@novusbio.com

Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NBP2-54370FR

Updated 10/23/2024 v.20.1

Earn rewards for product reviews and publications.

Submit a publication at www.novusbio.com/publications Submit a review at www.novusbio.com/reviews/destination/NBP2-54370FR



NBP2-54370FR

CD79A Antibody (IGA/1406) [DyLight 680]

0270717411100dy (10741100) [232	g-n e
Product Information	
Unit Size	100 ul
Concentration	Please see the vial label for concentration. If unlisted please contact technical services.
Storage	Store at 4C in the dark.
Clonality	Monoclonal
Clone	IGA/1406
Preservative	0.05% Sodium Azide
Isotype	IgG3 Kappa
Conjugate	DyLight 680
Purity	Protein A or G purified
Buffer	50mM Sodium Borate
Product Description	
Description	This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.
Host	Mouse
Gene ID	973
Gene Symbol	CD79A
Species	Human
Marker	B-Cell Marker
Specificity/Sensitivity	A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.
Immunogen	A synthetic peptide corresponding to aa 202-216 (GTYQDVGSLNIADVQ) of human CD79A protein. (Uniprot: P11912)
Notes	DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
Product Application Details	
Applications	Western Blot, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, CyTOF-ready
Recommended Dilutions	Western Blot, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, CyTOF-ready
Application Notes	Optimal dilution of this antibody should be experimentally determined.





Novus Biologicals USA

10730 E. Briarwood Avenue Centennial, CO 80112

USA Phone: 303.730.1950 Toll Free: 1.888.506.6887

Fax: 303.730.1966

nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave Toronto, ON M8Z 4E6

Canada

Phone: 905.827.6400 Toll Free: 855.668.8722 Fax: 905.827.6402

canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane Abingdon Science Park Abingdon, OX14 3NB, United Kingdom

Phone: (44) (0) 1235 529449 Free Phone: 0800 37 34 15 Fax: (44) (0) 1235 533420 info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com

Technical Support: nb-technical@bio-

techne.com

Orders: nb-customerservice@bio-techne.com

General: novus@novusbio.com

Products Related to NBP2-54370FR

NBP2-60209-50ug Recombinant Human CD79A His Protein

7268-CT-100 CTLA-4 [Unconjugated] 9685-CD-050 CD79A [Unconjugated]

AF114 CD45 Antibody [Unconjugated]

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP2-54370FR

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications

